The optimal choice for
reducing health risks.
Optimum-filter reduces the toxicity and carcinogenicity of tobacco smoke.
The antioxidant properties of Optimum-Filter complement the unique filter effects. Optimum-Filter does not diminish the joy of smoking.
Materials for the filter additive are aboundantly available and they can be manufactured at acceptable costs.
Optifilter Research R & D LTD was founded in 2014. It is a project company established around the intellectual property of the novel additives for cigarette filter, which incorporated in cigarette filters provides biological protection against tobacco smoke ingredients. In 2015 a financial Investor X-Ventures bought a minority interest in the company by increasing the shareholder’s capital of Optifilter Research Ltd.
After completing his studies (Duisburg Universität, the University of California at Santa Barbara), he has been working for several European trade and investment companies as Charmain and CEO, or as part of the management. His main fields of interest are trade, real estate development, investment, R&D. He has been the Chairman and CEO of Optimum-Filter R&D Company since 2006.
Ph.D in Pharmacy. Inventor, Head of material R&D. Formerly Head of Radioanalytical and Organic Microanalytical Laboratory in Institute of Isotopes, National Atomenergy Commission, Hungary and since 1968 member of the Hungarian Academy of Sciences. Humbold-Scholar in Central Research Institute of Atomenergy, Radiochemical and Analytical Departe of Federal Research Center of Food (Karlsruhe, Germany). Head of Analytical, Quality Control and Clinical Chemistry Deparment of Institute of Isotopes, Hungarian Academy of Sciences (Budapest, Hungary).
Ph.D. in Genetics at Albert Einstein College of Medicine. Currently he is the President and Chairman of Porton International Inc. – a private biopharmaceutical company (part of the Beaufour Ipsen Pharmaceutical Group) with headquarters in London and Washington, D.C. Before, Dr. Harsanyi was Vice President of E.F. Hutton and Company, New York where his group financed and established companies in the biotechnology field. Before turning to corporate finance he served as Project Director for genetics a the United States Congress, Office of Technology Assessment.
Ph.D. in Pharmacy at the Semmelweis Medical School, Budapest. He worked for different pharmacuetical companies (EGIS, Biopharm R&D, Medipharma R&D) and the Ministry of Health State Secretary. He had been the president of Hungarian Chamber of Pharmacists for eight years.
B. A. at the Academy for Foreign Trade, Budapest (Hungary). He has been in finance since 1977. He worked at Medicor, Nigeria (1981-85) dealing with medical equipment in 23 African countries; was the founder and the Managing Director of companies (John Bull Pub joint venture, Hungraphics, Novotrade), consultancies (i.e. Consultrade), R&D companies (i.e. Celladam Cancer Research, Biorex). Since 1997, he has been working as the Chairman and CEO of the double-barnched N-Gene Research Laboratories Inc. (New York, Budapest).
B.A. in chemistry at Columbia University, New York. Ph.D. in organic chemistry at the University of Michigan (1966). Three years of postdoctoral work at the University of New Orleans and the University of Texas after which he joined the faculty of the School of Public Health at the University of Pittsburgh in 1969 as a reasearcher of gamma rays on aqueous sugar solutions. In 1973 he joined Philip Morris in Richmond, Virginia, a company at which he worked until his retirement in 2008. He was the Manager of the Chemical Research Division in 1979 supervising work in smoke chemistry in addition to the chemical research already mentioned.
Ph.D. in Economics at the University of Basel. He worked for long decades at leading corporations (Nestlé Headquarters, Hoffman-La Roche Pharmaceuticals & Diagnostics). He was involved in worldwide developments in the field of corporate planning, marketing, controlling, finance. Since retiring, he has been a consultant for companies.
Dr. Chris Coggins is a Board-Certified Toxicologist, a qualification he has held since 1986, and a U.K. Registered Toxicologist. He is a Principal in Carson Watts Consulting, with special expertise in inhalation toxicology, general toxicology, toxicological pathology, and epidemiology. Prior to becoming a consultant in 2003, Dr. Coggins worked in various sectors of the tobacco industry. He was with Lorillard Tobacco in Greensboro NC, for 6 years, and with R.J. Reynolds in Winston-Salem NC, for 12 years. Prior to that Dr. Coggins worked at the Battelle-Geneva laboratory in Switzerland, for 10 years. Dr. Coggins obtained his Ph.D. from the University of Edinburgh (Scotland) in 1976 and obtained his bachelor's degree from the University of Glasgow in 1972. He has published extensively on the toxicology of tobacco smoke.
A Veterinary Specialist in Toxicology. He is responsible for the overall conducting of the Pharmaceutical Control and Developing Laboratory Co. Ltd. ( PC & DL ). He is an occasional lecturer at the Pharmacological Dept. of the Veterinary University, having several memberships of Learned Societies (Hungarian Pharmacol. Society, International Arteriosclerosis Society, Hungarian Human Genetic Society, European Toxicological Society, Hungarian Toxicological Society) His research achievements include about 15 patents granted in Hungary, Europe and USA. His numerous of publications have appeared in prestegious national and international journals.